A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Despite the recent success of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of Waldenstrom macroglobulinemia (WM), their indefinite treatment duration ultimately tantamount to substantial financial and emotional burden. On the other hand, fixed duration of proteasome inhibitors (PI) have shown rapid and reasonable response in WM treatment. Despite the well-known synergism between PI and immunomodulatory drugs (IMiD), there is no trials evaluating such combination in WM.Materials and Methods Based on above, we designed this phase II study to investigate the efficacy and safety of 6 cycles of 28-day bortezomib-thalidomide-dexamethasone (VTD) regimen for treatment-naïve WM.Results A total of 15 patients were enrolled: major response rate was 64.3%, and overall response rate was 78.6%. During the median follow-up of 41 months, median progression-free survival (PFS) was 13 months and overall survival 40 months. For responders, median duration of response was 13 months and median PFS 19 months. The most common adverse event (AE) of any grade was constipation (57.1%). The most common grade ≥ 3 AE was anemia (21.4%).Conclusion All in all, we hereby provide proof-of-concept that PI + IMiD may be an attractive backbone for fixed duration treatment. It should be noted that granting the same level of access to newer drugs globally is virtually impossible. Thus efforts to develop regimens using readily available drugs to yield similar or adequate treatment outcomes should not be disregarded. In this sense, we believe our study holds its place for its novelty and eloquently addresses achieving the daunting societal quest of health equity.
Abstract
Purpose Despite the recent success of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of Waldenstrom macroglobulinemia (WM), their indefinite treatment duration ultimately tantamount to substantial financial and emotional burden. On the other hand, fixed duration of proteasome inhibitors (PI) have shown rapid and reasonable response in WM treatment. Despite the well-known synergism between PI and immunomodulatory drugs (IMiD), there is no trials evaluating such combination in WM.Materials and Methods Based on above, we designed this phase II study to investigate the efficacy and safety of 6 cycles of 28-day bortezomib-thalidomide-dexamethasone (VTD) regimen for treatment-naïve WM.Results A total of 15 patients were enrolled: major response rate was 64.3%, and overall response rate was 78.6%. During the median follow-up of 41 months, median progression-free survival (PFS) was 13 months and overall survival 40 months. For responders, median duration of response was 13 months and median PFS 19 months. The most common adverse event (AE) of any grade was constipation (57.1%). The most common grade ≥ 3 AE was anemia (21.4%).Conclusion All in all, we hereby provide proof-of-concept that PI + IMiD may be an attractive backbone for fixed duration treatment. It should be noted that granting the same level of access to newer drugs globally is virtually impossible. Thus efforts to develop regimens using readily available drugs to yield similar or adequate treatment outcomes should not be disregarded. In this sense, we believe our study holds its place for its novelty and eloquently addresses achieving the daunting societal quest of health equity.
참고문헌 (23)
- Castillo JJ, "Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia", Lancet Haematol, 7, pp.e827~37 (2020)
- Gertz MA, "Waldenstrom macroglobulinemia : 2023 update on diagnosis, risk stratification, and management", Am J Hematol, 98, pp.348~358 (2023)
- Staber PB, "EHA endorsement of ESMO clinical practice guidelines for diagnosis, treatment, and follow-up for Waldenstrom’s macroglobulinemia", Hemasphere, 5, pp.e634~ (2021)
- Kastritis E, "Waldenstrom’s macroglobulinaemia : ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 30, pp.860~862 (2019)
- Buske C, "Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstrom’s macroglobulinemia : final analysis from the randomized phase III iNNOVATE study", J Clin Oncol, 40, pp.52~62 (2022)
- Tam CS, "A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia : the ASPEN study", Blood, 136, pp.2038~2050 (2020)
- Hatashima A, "Approved and emerging Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia", Expert Opin Pharmacother, 23, pp.1545~1557 (2022)
- Castillo JJ, "Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia", Haematologica, 103, pp.e307~e310 (2018)
- Ghobrial IM, "Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia", Am J Hematol, 85, pp.670~674 (2010)
- Dimopoulos MA, "Bortezomib as a treatment option in patients with Waldenstrom macroglobulinemia", Clin Lymphoma Myeloma Leuk, 10, pp.110~117 (2010)
- Dimopoulos MA, "Treatment of Waldenstrom’s macroglobulinemia with thalidomide", J Clin Oncol, 19, pp.3596~3601 (2001)
- Dimopoulos MA, "Treatment of Waldenstrom’s macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone", Semin Oncol, 30, pp.265~269 (2003)
- Jeong S, "Incidence, prevalence, mortality, and causes of death in Waldenstrom macrog-lobulinemia : a nationwide, population-based cohort study", BMC Cancer, 20, pp.623~ (2020)
- Owen RG, "Developing diagnostic criteria in Waldenstrom’s macroglobulinemia", Semin Oncol, 30, pp.196~200 (2003)
- Treon SP, "How I treat Waldenstrom macroglobulinemia", Blood, 126, pp.721~732 (2015)
- Varghese AM, "Assessment of bone marrow response in Waldenstrom’s macroglobulinemia", Clin Lymphoma Myeloma, 9, pp.53~55 (2009)
- Dimopoulos MA, "Primary therapy of Waldenstrom macroglobulinemia(WM)with weekly bortezomib, low-dose dexamethasone, and rituximab(BDR) : long-term results of a phase 2 study of the European Myeloma Network(EMN)", Blood, 122, pp.3276~3282 (2013)
- "Clinical practice guidelines in oncology, Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, version 1.2023" (2023)[URL]
- Treon SP, "Thalidomide and rituximab in Waldenstrom macroglobulinemia", Blood, 112, pp.4452~4457 (2008)
- Buske C, "Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstrom’s macroglobulinemia : a prospectively rando-mized trial of the European Consortium for Waldenstrom’s Macroglobulinemia", J Clin Oncol, 41, pp.2607~2616 (2023)
- McLaughlin P, "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four-dose treatment program", J Clin Oncol, 16, pp.2825~2833 (1998)
- Aksoy S, "Infectious complications of rituximab in patients with lymphoma during maintenance therapy : a systematic review and meta-analysis", Leuk Lymphoma, 50, pp.357~365 (2009)
- Abeykoon JP, "MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia", Am J Hematol, 93, pp.187~194 (2018)